Abstract
Platelet-activating factor (PAF) is a phosphatidylcholine containing a long-chain alkyl ether at position 1 and an acetate ester at position 2 (Blank et al., 1979; Demopoulos et al., 1979; Polonsky et al., 1980):
Various cell types form and secrete this product when stimulated. PAF is found in the blood of animals undergoing experimentally induced toxic reactions such as anaphylaxis, serum sickness, and endotoxemia. It can mimic these reactions when injected intravenously into healthy animals. In particular, PAF infusion produces the activation of intravascular leukocytes and platelets, contraction of pulmonary airways, vascular instability, enhanced capillary permeability, and cardiac abnormalities. Deposited locally into tissues, PAF promotes edema and leukocyte accumulation. These results implicate PAF as a mediator of allergic and inflammatory reactions. However, even the most complex, systemic effects of PAF must result from fundamental interactions with target cells. Some understanding of these interactions has been obtained using in vitro studies on tissues containing one or only a few cell types.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Avdonin, P. V., Svitina-Ulitina, I. V., and Kulikov, V. I., 1985, Stimulation of high-affinity hormone-sensitive GTPase of human platelets by l-0-alkyl-2-0-acetyl-sn-glyceryl-3-phosphocholine (platelet activating factor), Biochem. Biophys. Res. Commun. 131:307–313.
Beaubien, B. B., Tippins, J. R., and Morris, H. R., 1984, Platelet-activating factor stimulation of peptidoleukotriene release: Inhibition by vasoactive polypeptide, Biochem. Biophys. Res. Commun. 125:105–108.
Berridge, M. J., and Irvine, R. F., 1984, Inositol trisphosphate, a novel second messenger in cellular signal transduction, Nature 312:317–321.
Blank, M. L., Snyder, F., Byers, L. W., Brooks, B., and Muirhead, E. E., 1979, Antihypertensive activity of an alkyl ether analog of phosphatidylcholine, Biochem. Biophys. Res. Commun. 90:1194–1200.
Blank, M. L., Cress, E. A., Lee, T.-C., Malone, B., Surles, J. R., Piantadosi, C., Hajdu, J., and Snyder, F., 1982, Structural features of platelet activating factor (l-alkyl-2-acetyl-sn-glycero-3-phosphocholine) required for hypotensive and platelet serotonin responses, Res. Commun. Chem. Pathol. Pharmacol. 38:3–20.
Camussi, G., Montrucchio, G., Antro, C., Bussolino, F., Tetta, C., and Emanuelli, G., 1983, Platelet-activating factor-mediated contraction of rabbit lung strips: Pharmacologic modulation, Immunopharmacology 6:87–96.
Cazenave, J. P., Benveniste, J., and Mustard, J. F., 1979, Aggregation of rabbit platelets by platelet-activating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane-active drugs, Lab. Invest. 41:275–285.
Chesney, C. M., Pifer, D. D., Byers, L. W., and Muirhead, E. E., 1982, Effect of platelet-activating factor (PAF) on human platelets, Blood 59:582–585.
Chesney, C.M., Pifer, D. D., and Huch, K. M., 1983, Alpha-adrenergic antagonists inhibit binding of platelet-activating factor (PAF) to human gel-filtered platelets, J. Pharmacol. 14:21 (Suppl. 1).
Chesney, C. M., Pifer, D. D., and Huch, K. M., 1985, Desensitization of human platelets by platelet activating factor, Biochem. Biophys. Res. Commun. 127:24–30.
Chilton, F. H., O’Flaherty, J. T., Walsh, C. E., Thomas, M. J., Wykle, R. L., DeChatelet, L. R., and Waite, B. M., 1982, Platelet activating factor: Stimulation of the lipoxygenase pathway in polymorphonuclear leukocytes by l-0-alkyl-2-0-acetyl-sn-glycero-3-phosphocholine, J. Biol. Chem. 257:5402–5407.
Dahl, M. L., 1985, Aggregating and prostanoid-releasing effects of platelet-activating factor and leuko-trienes on human polymorphonuclear leukocytes and platelets, Int. Arch. Allergy Appl. Immunol. 76:145–150.
Demopoulos, C. A., Pinckard, R. N., and Hanahan, D. J., 1979, Evidence for l-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators), J. Biol. Chem. 254:9355–9358.
Doebber, T. W., Wu, M. S., Robbins, J. C., Choy, B. M., Chang, M. N., and Shen, T. Y., 1985, Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonists kadsurenone, Biochem. Biophys. Res. Commun. 127:799–808.
Ford-Hutchinson, A. W., 1983, Neutrophil aggregating properties of PAF-acether and leukotriene B4, Int. J. Immunopharmacol. 5:17–21.
Gorman, R. R., Morton, D. R., Hopkins, N. K., and Lin, A. H., 1983, Acetyl glyceryl ether phos-phorylcholine stimulates leukotriene B4 synthesis and cyclic AMP accumulation in human polymorphonuclear leukocytes, Adv. Prostaglandin, Thromboxane, Leukotriene Res. 12:57–63.
Hallam, T. J., Rink, T. J., and Sanchez, A., 1983, Elevation of cytoplasmic calcium concentration in human platelets by platelet-activating factor, Br. J. Pharmacol. 79:35IP.
Hartung, H. P., 1983, Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2 production, spreading, and the influence of calmodulin-inhibitor W-7, FEBS Lett. 160:209–212.
Haslam, R. J., and Vanderwell, M., 1982, Inhibition of platelet adenylate cyclase by l-O-alkyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor), J. Biol. Chem. 257:6879–6885.
Heymans, F., Borrel, M. C., Broquet, C., Lefort, J., and Godfroid, J. J., 1985, Structure-activity relationship in PAF-acether. 2. rac-l-0-octadecyl-2-0-acetyl-3-0-[(dimethyl amino)propyl]glyc-erol, J. Med. Chem. 28:1094–1096.
Hwang, S. B., Lee, C. S. C., Cheah, M. J., and Shen, T. Y., 1983, Specific receptor sites for l-O-alkyl-2-0-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) on rabbit platelet and guinea pig smooth muscle membranes, Biochemistry 22:4756–4763.
Hwang, S. B., Lam, M. H., and Pong, S. S., 1985, Regulation of 3H-PAF binding to its receptors by ions and GTP and PAF-induced activation of GTPase in rabbit platelet membranes, October 15–18, 1985, New Horizons in Platelet Activating Factor Research, Mariner’s Inn, Palmetto Dunes Resort, Hilton Head Island, South Carolina.
Ieyasu, H., Takai, Y., Kaibuchi, K., Sawamura, M., and Nishizuka, Y., 1982, A role of calcium-activated, phospholipid-dependent protein kinase in platelet-activating factor-induced serotonin release from rabbit platelets, Biochem. Biophys. Res. Commun. 108:1701–1708.
Ingraham, L. M., Coates, T. D., Allen, J. M., Higgins, C. P., Baehner, R. L., and Boxer, L. A., 1982, Metabolic, membrane, and functional responses of human polymorphonuclear leukocytes to platelet-activating factor, Blood 59:1259–1266.
Irvine, R. F., 1982, How is the level of free arachidonic acid controlled in mammalian cells?, Biochem. J. 204:3–16.
Kawaguchi, H., and Yasuda, H., 1984, Platelet-activating factor stimulates phospholipase in quiescent Swiss mouse 3T3 fibroblast, FEBS Lett. 176:93–96.
Kenzora, J. L., Perez, J. E., Bergmann, S. R., and Lange, L. G., 1984, Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs, J. Clin. Invest. 74:1193–1203.
Khan, S. N., Lane, P. A., and Smith, A. D., 1985, Disaggregation of PAF-acether-aggregated platelets by verapamil and TMB-8 with reversal of phosphorylation of 40K and 20K proteins, Eur. J. Pharmacol. 107:189–198.
Kornecki. E., Ehrlich, Y. H., and Lenox, R. H., 1984. Platelet-activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines. Science 226:1454–1456.
Lad, P. M., Olson. C. V., and Grewal. I. S., 1985a, Platelet activating factor and other mediators of inflammation act through a pertussis toxin sensitive GTP binding protein, October 15–18. New Horizons in Platelet Activating Factor Research, Mariner’s Inn, Palmetto Dunes Resort, Hilton Head Island, South Carolina.
Lad. P. M., Olson. C. V., and Grewal. I. S., 1985b, Platelet-activating factor mediated effects on human neutrophil function are inhibited by pertussis toxin. Biochem. Biophys. Res. Commun. 129:632-638.
Lanara, E., Vakirtzi-Lemonias, C., Kritikou, L., and Demopoulos, C. A., 1982, Response of mice and mouse platelets to acetyl glyceryl ether phosphorylcholine. Biochem. Biophys. Res. Commun. 109:1148–1156.
Lapetina, E. G., and Siegel, F. L., 1982, Shape change induced in human platelets by platelet-activating factor, J. Biol. Chem. 258:7241–7244.
Lee, T., Malone, B., Blank. M. L., and Snyder, F., 1981, l-alkyl-2-acetyl-sn-glycero-3-phos-phocholine (platelet-activating factor) stimulates calcium influx in rabbit platelets, Biochem. Biophys. Res. Commun. 102:1262-1268.
Lee, T., Malone, B., and Snyder, F., 1983, Stimulation of calcium uptake by l-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) in rabbit platelets: Possible involvement of the lipoxygenase pathway, Arch. Biochem. Biophys. 223:33-39.
Lewis. A. J., Dervinis. A., and Chang, J., 1984, The effects of antiallergic and bronchodilator drugs on platelet-activating factor (PAF-acether) induced bronchospasm and platelet aggregation, Agents Actions 15:636–642.
Lewis, R. A., and Austen, K. F., 1984, The biologically active leukotrienes biosynthesis, metabolism, receptors, functions, and pharmacology, J. Clin. Invest. 73:889-897.
Lin, A. H., Morton, D. R., and Gorman, R. R., 1982, Acetyl glyceryl ether phosphorylcholine stimulates leukotriene B4 synthesis in human polymorphonuclear leukocytes, J. Clin. Invest. 70:1058–1065.
Marcus, A. J., Safier, L. B., Ullman, H. L., Wong, K. T. H., Broekman. M. J., Weksler, B. B., and Kaplan, K. L., 1981, Effects of acetyl glyceryl ether phosphorylcholine on human platelet function in vitro, Blood 58:1027–1031.
Maridonneau-Parini, I., Lagente, V., Lefort, J., Randon, J., Russo-Marie, F., and Vargaftig, B. B., 1985, Desensitization to PAF-induced bronchoconstriction and to activation of alveolar macrophages by repeated inhalations of PAF in the guinea pig, Biochem. Biophys. Res. Commun. 131:42–49.
Mauco, G., Chap, H., and Douste-Blazy, L., 1983, Platelet activating factor (PAF-acether) promotes an early degradation of phosphatidylinositol-4,5-biphosphate in rabbit platelets, FEBS Lett. 153:361– 365.
Mendlovic, F., Corvera, S., and Garcia-Sainz, J. A., 1984, Possible involvement of cyclooxy-genase products in the actions of platelet-activating factor and of lipoxygenase products in the vascular effects of epinephrine in perfused rat liver, Biochem. Biophys. Res. Commun. 123:507–514.
Mueller, H. W., O’Flaherty, J. T., and Wykle, R. L., 1983, Biosynthesis of platelet activating factor in rabbit polymorphonuclear neutrophils, J. Biol. Chem. 258:6213–6218.
Nishihira, J., and O’Flaherty, J. T. ,1985, Phorbol myristate acetate receptors in human polymorphonuclear neutrophils, J. Immunol. 135:3439–3447.
Nishihira, J., Ishibashi, T., Imai, Y., and Muramatsu, T., 1986, Purification and characterization of the specific binding protein for platelet activating factor (l-0-alkyl-2-acetyl-sn-glycero-3-phos-phocholine) from human platelets, Tohoku J. Exp. Med. (in press).
Nishizuka, Y., 1984, The role of protein kinase C in cell surface signal transduction and tumour promotion, Nature 308:639–697.
O’Flaherty, J. T., 1982, Biology of disease. Lipid mediators of inflammation and allergy, Lab. Invest. 47:314–329.
O’Flaherty, J. T., 1985, Neutrophil degranulation: Evidence pertaining to its mediation by the combined effects of leukotriene B4, platelet-activating factor, and 5-HETE, J. Cell. Physiol. 122:229–239.
O’Flaherty, J. T., Miller, C. H., Lewis, J. C., Wykle, R. L., Bass, D. A., McCall, C. E., Waite, M., and DeChatelet, L. R., 1981a, Neutrophil responses to platelet-activating factor, Inflammation 5:193–201.
O’Flaherty, J. T., Swendsen, C. L., Lees, C. J., and McCall, C. E., 1981b, Role of extracellular calcium in neutrophil degranulation responses to l-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine, Am. J. Pathol. 105:107–113.
O’Flaherty, J. T., Lees, C. J., Miller, C. H., McCall, C. E., Lewis, J. C, Love, S. H., and Wykle, R. L., 1981c, Selective desensitization of neutrophils: Further studies with l-O-alkyl-srt-glycero-3-phosphocholine analogues, J. Immunol. 127:731–737.
O’Flaherty, J. T., Hammett, M. J., Shewmake, T. B., Wykle, R. L., Love, S. H., McCall, C. E., and Thomas, J. M., 198Id, Evidence for 5,12-dihydroxy-6,8,10,14-eicosatetraenoate as a mediator of human neutrophil aggregation, Biochem. Biophys. Res. Commun. 103:552–558.
O’Flaherty, J. T., Wykle, R. L., McCall, C. E., Shewmake, T. B., Lees, C. J., and Thomas, M., 198le, Desensitization of the human neutrophil degranulation response: Studies with 5,12-di-hydroxy-6,8,10,14-eicosatetraenoic acid, Biochem. Biophys. Res. Commun. 101:1290–1296.
O’Flaherty, J. T., Salzer, W. L., Cousart, S., McCall, C. E., Piantadosi, C., Surles, J. R., Hammett, M. J., and Wykle, R. L., 1983, Platelet-activating factor and analogues: Comparative studies with human neutrophils and rabbit platelets, Res. Commun. Chem. Pathol. Pharmacol. 39:291–309.
O’Flaherty, J. T., Schmitt, J. D., Wykle, R. L., Redman, J. F., and McCall, C. E., 1985, Di-acylglycerols and Mezerein activate neutrophils by a phorbol myristate acetate-like mechanism, J. Cell. Phys. 125:192–199.
O’Flaherty, J., Kosfeld, S., and Nishihira, J., 1986, Binding and metabolism of leukotriene B4 by neutrophils and their subcellular organelles, J. Cell. Physiol. 126:359–370.
Pfeilschifter, J., Kurtz, A., and Bauer, C., 1985, Inhibition of renin secretion by platelet activating factor (acetylglyceryl ether phosphorylcholine) in cultured rat renal juxtaglomerular cells, Biochem. Biophys. Res. Commun. 127:093–910.
Polonsky, J., Tence, M., Varenne, P., Das, B.C., Lunel, J., and Benveniste, J., 1980, Release of l-O-alkylglyceryl-3-phosphorylcholine, O-deacetyl platelet-activating factor, from leukocytes: Chemical ionization mass spectrometry of phospholipids, Proc. Natl. Acad. Sci. USA 77:7019–7023.
Samuelsson, B., 1982, The leukotrienes: An introduction, in Leukotrienes and Other Lipoxygenase Products (B. Samuelsson and R. Paoletti, eds.), Raven Press, New York.
Satouchi, K., Pinckard, R. N., McManus, L. M., and Hanahan, D. J., 1981, Modification of the polar head group of acetyl glyceryl ether phosphorylcholine and subsequent effects upon platelet activation, J. Biol. Chem. 256:4425–4432.
Shaw, J. O., and Lyons, R. M., 1982, Requirements for different CaJ. T.+ pools in the activation of rabbit platelets, Biochim. Biophys. Acta 714:492–499.
Shaw, J. O., Printz, M. P., Hirabayashi, K., and Henson, P. M., 1978, Role of prostaglandin synthesis in rabbit platelet activation induced by basophil-derived platelet-activating factor, J. Immunol. 121:1939–1945.
Shaw, J. O., Pinckard, R. N., Ferrigni, K. S., McManus, L. M., and Manahan, D. J., 1981, Activation of human neutrophils with l-0-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet activating factor), J. Immunol. 127:1250–1255.
Shen, T. Y., Hwang, S., Cheah, M. J., and Lee, C. C., 1983, Effects of nonsteroid antiinflammatory drugs (NSAIDS) on the specific binding of platelet activating factor (PAF) to membrane preparations of rabbit platelets, J. Pharmacol. 14:20.
Shen, T. Y., Hwang, S., Chang, M. N., Doebber, T. W., Lam, M. T., Wu, M. S., Wang, X., Han, G. Q., and Li, R. Z., 1985, Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura) Specific inhibition of in vitro and in vivo platelet-activating factor-induced effects, Proc. Natl. Acad. Sci. USA 82:672–676.
Shukla, D. D., and Hanahan, D. J., 1982, AGEPC (platelet activating factor) induced stimulation of rabbit platelets: Effects on phosphatidylinositol, di-and tri-phosphoinositides and phosphatidic acid metabolism, Biochem. Biophys. Res. Commun. 106:697–703.
Shukla, S. D., Buxton, D. B., Olson. M. S., and Hanahan, D. J., 1983, Acetylglyceryl ether phos-phorylcholine. A potent activator of hepatic phosphoinositide metabolism and glycogenosis, J. Biol. Chem. 258:10212–10214.
Smith, R. J., Bowman, B. J., and Iden, S. S., 1984, Stimulation of the human neutrophil superoxide anion-generating system with 1 -0-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorycholine, Biochem. Pharmacol. 33:973–978.
Stimler, N. P., 1985, Parasympathetic stimulation as a mechanism for PAF-induced contractile responses in lung, October 15–18, New Horizons in Platelet Activating Factor Research, Mariner’s Inn, Palmetto Dunes Resort, Hilton Head Island, South Carolina.
Stimler, N. P., and O’Flaherty. J. T., 1983, Spasmogenic properties of platelet-activating factor: Evidence for a direct mechanism in the contractile response of pulmonary tissues, Am. J. Pathol. 113:75–84.
Stimler, N. P., Bloor, C. M., Hugli, T. E., Wykle, R. L., McCall, C. E., and O’Flaherty, J. T., 1981, Anaphylactic actions of platelet-activating factor, Am. J. Pathol. 105:64–69.
Stimler, N. P., Gerard, C, and O’Flaherty, J. T., 1983, Contraction of human lung tissues by platelet-activating factor (AAGPC), INSERMS 23:195–204.
Surles. J. R., Wykle, R. L., O’Flaherty, J. T., Salzer, W. L., Thomas, M. J., Snyder, P., and Piantadosi, C., 1984, Facile synthesis of platelet-activating fetor and racemic analogues containing unsaturation in the sn-1-alkyl chain, J. Med. Chem. 28:73–78.
Swendsen, C. L., Ellis, J. M., Chilton, F. H., III, O’Flaherty, J. T., and Wykle, R. L., 1983, 1–0-alkyl-2-acyl-sn-glycero-3-phosphocholine: A novel source of arachidonic acid in neutrophils stimulated by the calcium ionophore A23187, Biochem. Biophys. Res. Commun. 113:72–79.
Terashita, Z., Tsushima, S., Yoshioka, Y., Nomura, H., Inada, Y., and Nishikawa, K., 1983, CV-3988—A specific antagonist of platelet activating factor (PAF), Life Sci. 32:1975–1982.
Tokumura, A., Homma, H., and Hanahan, D. J., 1985, Structural analogs of alkylacetylglycerophos-phocholine inhibitory behavior on platelet activation, J. Biol. Chem. 260:12710–12714.
Valone, F. H., 1984, Isolation of a platelet membrane protein which binds the platelet-activating factor l-0-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine, Immunology 52:169–174.
Valone, F. H., 1985a, Inhibition of binding of the platelet-activating factor AGEPC to platelets by the AGEPC analog rac-3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl-2-thiazolioethyl phosphate (CV-3988), Biochem. Biophys. Res. Comm. 126:502–508.
Valone, F. H., 1985b, Inhibition of PAF binding by the calcium channel blockers diltiazem (Dil) and verapamil (Ver), October 15–18, New Horizons in Platelet Activating Factor Research, Mariner’s Inn, Palmetto Dunes Resort, Hilton Head Island, South Carolina.
Valone, F. H., and Goetzl, E. J., 1983, Specific binding by human polymorphonuclear leucocytes of the immunological mediator l-0-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine. Immunology 48:141–148.
Valone, F. H., Coles, E., Reinhold, V. R., and Goetzl, E. J., 1982, Specific binding of phospholipid platelet-activating factor by human platelets, J. Immunol. 129:1637–1641.
Voelkel, N. F., Worthen, S., Reeves, J. T., Henson, P. M., and Murphy, R. C, 1982, Nonim-munological production of leukotrienes induced by platelet-activating factor, Science 218:286–288.
White, G. C, II, 1984, Effect of l-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine on calcium fluxes by human platelet microsomes, Biochem. Biophys. Res. Commun. 120:474–480.
Williams, K. A., and Haslam, R. J., 1984, Effects of NaCl and GTP on the inhibition of platelet adenylate cyclase by l-0-octadecyl-2–0-acetyl-sn-glyceryl-3-phosphorylcholine (synthetic platelet-activating factor), Biochim. Biophys. Acta. 770:216–223.
Wissner, A., Sum, P. E., Schaub, R. E.. Kohler, C. A., and Goldstein, B. M., 1984, Analogues of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain, J. Med. Chem. 27:1174–1181.
Wykle, R. L., Miller, C. H., Lewis, J. C., Schmitt, J. D., Smith, J. A., Surles, J. R., Piantadosi, C., and O’Flaherty, J. T., 1981, Stereospecific activity of l-0-alkyl-2–0-acetyl-sn-glycero-3-phos-phocholine and comparison of analogs in the degranulation of platelets and neutrophils, Biochem. Biophys. Res. Commun. 100:1651–1658.
Wykle, R. L., Surles, J. R., Piantadosi, C., Salzer, W. L., and O’Flaherty, J. T., 1982, Platelet activating factor (l-0-alkyl-2–0-acetyl-sn-glycero-3-phosphocholine). Activity of analogs lacking oxygen at the 2-position, FEBS Lett. 141:29–32.
Yasaka, T., Boxer, L., and Baehner, R. L., 1982, Monocyte aggregation and superoxide anion release in response to formyl-methionyl-leucyl-phenylalanine (FMLP) and platelet-activating factor (PAF), J. Immunol. 128:1939–1944.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Plenum Press, New York
About this chapter
Cite this chapter
O’Flaherty, J.T. (1987). Platelet-Activating Factor: Mechanisms of Cellular Activation. In: Snyder, F. (eds) Platelet-Activating Factor and Related Lipid Mediators. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5284-6_13
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5284-6_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5286-0
Online ISBN: 978-1-4684-5284-6
eBook Packages: Springer Book Archive